Biovail Laboratories International has entered into a license agreement with Kyowa Hakko Kirin Co. under which Biovail has acquired the U.S. and Canadian rights to commercialize products containing istradefylline, a new chemical entity targeted for the treatment of Parkinson’s disease. Biovail has paid an upfront fee of $10 million, and could pay as much as $20 million in potential development milestones and $35 million in sales-based milestones. Biovail will also make tiered, royalty payment...